| Primary |
| Prophylaxis Of Nausea And Vomiting |
44.8% |
| Nausea |
8.4% |
| Chemotherapy |
8.0% |
| Premedication |
4.8% |
| Breast Cancer |
4.7% |
| Prophylaxis |
4.1% |
| Vomiting |
3.6% |
| Product Used For Unknown Indication |
3.1% |
| Lung Neoplasm Malignant |
2.9% |
| Colon Cancer |
2.4% |
| Neoplasm Malignant |
1.9% |
| Ovarian Cancer |
1.7% |
| Acute Myeloid Leukaemia |
1.5% |
| Gastric Cancer |
1.3% |
| Hypertension |
1.3% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Antiemetic Supportive Care |
1.2% |
| Breast Cancer Metastatic |
1.2% |
| Lymphoma |
1.0% |
| Small Cell Lung Cancer Stage Unspecified |
1.0% |
|
| Death |
8.9% |
| Vomiting |
8.9% |
| Encephalopathy |
7.9% |
| Nausea |
7.9% |
| Convulsion |
7.3% |
| Flushing |
7.3% |
| Drug Interaction |
6.3% |
| Infusion Site Pain |
4.4% |
| Epilepsy |
4.1% |
| Anaphylactic Reaction |
3.8% |
| Neutropenia |
3.8% |
| Pain |
3.8% |
| Paraesthesia |
3.8% |
| Tachycardia |
3.5% |
| Cytolytic Hepatitis |
3.2% |
| Headache |
3.2% |
| Product Quality Issue |
3.2% |
| Pruritus |
3.2% |
| Drug Ineffective |
2.8% |
| Dyspnoea |
2.8% |
|
| Secondary |
| Prophylaxis Of Nausea And Vomiting |
24.8% |
| Product Used For Unknown Indication |
12.7% |
| Breast Cancer |
7.4% |
| Premedication |
7.4% |
| Chemotherapy |
6.7% |
| Nausea |
6.6% |
| Prophylaxis |
5.3% |
| Vomiting |
3.9% |
| Drug Use For Unknown Indication |
3.1% |
| Acute Lymphocytic Leukaemia |
2.9% |
| Neoplasm Malignant |
2.7% |
| Lymphoma |
2.6% |
| Colorectal Cancer |
2.2% |
| Lung Neoplasm Malignant |
2.2% |
| Pain |
1.9% |
| Colon Cancer |
1.6% |
| Acute Myeloid Leukaemia |
1.5% |
| Lung Adenocarcinoma |
1.5% |
| Hodgkin's Disease Stage Iii |
1.4% |
| Antiemetic Supportive Care |
1.4% |
|
| Vomiting |
11.2% |
| White Blood Cell Count Decreased |
8.0% |
| Cytolytic Hepatitis |
7.7% |
| Renal Failure Acute |
7.7% |
| Convulsion |
5.3% |
| Sudden Death |
5.1% |
| Encephalopathy |
4.8% |
| Thrombocytopenia |
4.8% |
| Drug Interaction |
4.5% |
| Dyspnoea |
4.3% |
| Hepatocellular Injury |
4.3% |
| Syncope |
4.3% |
| Paraesthesia |
4.0% |
| Hyponatraemia |
3.7% |
| Peripheral Sensory Neuropathy |
3.7% |
| Febrile Bone Marrow Aplasia |
3.5% |
| Flank Pain |
3.5% |
| Photosensitivity Reaction |
3.5% |
| Haemolytic Anaemia |
3.2% |
| Inappropriate Antidiuretic Hormone Secretion |
3.2% |
|
| Concomitant |
| Prophylaxis |
13.6% |
| Breast Cancer |
10.1% |
| Drug Use For Unknown Indication |
8.4% |
| Non-small Cell Lung Cancer |
8.3% |
| Prophylaxis Of Nausea And Vomiting |
8.2% |
| Nausea |
6.5% |
| Product Used For Unknown Indication |
6.4% |
| Premedication |
5.8% |
| Hypertension |
4.9% |
| Colorectal Cancer |
4.9% |
| Pain |
3.9% |
| Chemotherapy |
2.9% |
| Vomiting |
2.5% |
| Colon Cancer Metastatic |
2.3% |
| Lung Adenocarcinoma |
2.2% |
| Constipation |
2.1% |
| Colon Cancer |
1.8% |
| Abdominal Pain |
1.8% |
| Diarrhoea |
1.7% |
| Gastric Cancer |
1.6% |
|
| Vomiting |
14.0% |
| White Blood Cell Count Decreased |
9.2% |
| Pyrexia |
7.7% |
| Nausea |
6.8% |
| Renal Failure Acute |
5.6% |
| Neutropenia |
5.2% |
| Febrile Neutropenia |
5.0% |
| Pulmonary Embolism |
5.0% |
| Weight Decreased |
4.7% |
| Diarrhoea |
4.1% |
| Pneumonia |
3.9% |
| Dehydration |
3.8% |
| Hypertension |
3.5% |
| Interstitial Lung Disease |
3.5% |
| Pulmonary Alveolar Haemorrhage |
3.1% |
| Sepsis |
3.0% |
| Septic Shock |
3.0% |
| Syncope |
3.0% |
| Thrombocytopenia |
3.0% |
| Death |
2.9% |
|
| Interacting |
| Drug Use For Unknown Indication |
27.4% |
| Prophylaxis Of Nausea And Vomiting |
22.6% |
| Non-hodgkin's Lymphoma |
11.9% |
| Nausea |
7.1% |
| Sarcoma |
6.0% |
| Premedication |
3.6% |
| Adenocarcinoma |
2.4% |
| Bone Pain |
2.4% |
| Chemotherapy |
2.4% |
| Oral Candidiasis |
2.4% |
| Respiratory Disorder |
2.4% |
| Rhabdomyosarcoma |
2.4% |
| Uterine Leiomyosarcoma |
2.4% |
| Antiemetic Supportive Care |
1.2% |
| Pain |
1.2% |
| Product Used For Unknown Indication |
1.2% |
| Vomiting |
1.2% |
|
| Toxic Encephalopathy |
23.8% |
| Pancytopenia |
19.0% |
| Encephalopathy |
9.5% |
| Neurotoxicity |
9.5% |
| Weight Decreased |
9.5% |
| Aspartate Aminotransferase Increased |
4.8% |
| Drug Interaction |
4.8% |
| Infusion Site Extravasation |
4.8% |
| Mental Status Changes |
4.8% |
| Middle Insomnia |
4.8% |
| Renal Failure Acute |
4.8% |
|
